Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT03669666 Completed - Clinical trials for Valvular Heart Disease (Aortic and Mitral Valves)

Phase Contrast in Valvular Heart Disease

Start date: July 1, 2017
Phase:
Study type: Observational

The ability to quantify flow directly using through-plane phase contrast velocity mapping is a unique advantage of cardiovascular magnetic resonance and does not rely on the calculation from complex equations as echocardiography. The aim s is to study the role of cardiac MRI in the evaluation of valvular heart disease through quantification of the impact of valvular lesions upon cardiac function by accurate estimation of the left ventricular ejection fraction

NCT ID: NCT03669393 Completed - Clinical trials for Retinal Telangiectasis

A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

Start date: September 18, 2018
Phase: Phase 2
Study type: Interventional

This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in reducing central subfield thickness (CST) and improving best-corrected visual acuity (BCVA) in subjects with macular telangiectasia Type 1 (MacTel 1).

NCT ID: NCT03669289 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Enhanced Support for Behavioral Barriers to Learning: An Evaluation of the SCHOOL STARS Program

Start date: September 14, 2018
Phase: N/A
Study type: Interventional

This small pilot study will enroll children ages 5-12 years of age with disruptive behavior problems at school. These children and their families will be offered an enhanced model of primary care, which includes pre-visit record review, standardized content of primary care visits, post-visit care coordination by the primary care team, and coordination of services between the primary care team and the school. We hypothesize that children receiving this enhanced model of care will achieve better behavioral outcomes at both school and home.

NCT ID: NCT03669094 Completed - Clinical trials for Streptococcus Agalactiae Infection

Effect of a New Probiotic Strain in the Reduction of Group B Streptococcus Colonization in Pregnant Women

PROBIGEST
Start date: December 5, 2018
Phase: N/A
Study type: Interventional

An interventional, randomized, multicenter, double-blind, placebo-controlled, parallel-group study will be conducted to evaluate the effectiveness of the strain Lactobacillus salivarius V4II-90 in the reduction of Group B Streptococcus (GBS) colonization in pregnant women who are GBS carriers. Forty GBS-positive participants in their first trimester of pregnancy will be randomly assigned to one of the two study groups: The experimental group with 3 months probiotic consumption; and the control group with 3 months placebo consumption. The efficacy of the probiotic strain to reduce the incidence of Group B Streptococcus will be assessed by the percentage of participants with a vaginal and/or rectal detection of Group B Streptococcus at the end of the study, by bilateral comparison of the treatment group with the control group at the same time period. The estimated duration of the study will be 30 weeks, which includes a 3-month product administration. The intervention will start at week 23 ± 4 days of pregnancy and end at week 35 ± 4 days. Then, a visit will be completed one month after delivery.

NCT ID: NCT03669068 Completed - Clinical trials for Gastrointestinal Bleeding

Gastrointestinal Endoscopy in Patients With Prothrombotic Conditions: THE ENDOHEM REGISTRY

Start date: January 1, 2018
Phase:
Study type: Observational [Patient Registry]

This observational study evaluates the safety of gastrointestinal endoscopy in patients on oral anticoagulants (Vitamin K antagonists, rivaroxaban, dabigatran, edoxaban, and apixaban). This registry aims to assess the incidence, characteristics and risk factors for cardiovascular and bleeding events associated with an endoscopic procedure. Besides, it aims to evaluate the differences between Vitamin K antagonists and DOACs users and to estimate the impact of anticoagulation withdrawal time on the primary and secondary outcomes.

NCT ID: NCT03669042 Completed - Clinical trials for Peripheral Arterial Disease

Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular Surgery

PHOTO-V
Start date: November 20, 2018
Phase: N/A
Study type: Interventional

The objective of this post-market clinical follow-up study is to evaluate the clinical outcomes of patients receiving PhotoFix as a patch within a vascular repair or reconstruction procedure.

NCT ID: NCT03668795 Completed - Clinical trials for To Publish Our Experience in the Surgical Management to Placenta Accreta Cases and the Maternal Outcome

Surgical Management of Placenta Accreta

Start date: August 1, 2011
Phase:
Study type: Observational

purpose of this study was to report our experience for surgical management of suspected placenta accreta cases encountered in King Hussein medical center

NCT ID: NCT03668613 Completed - Clinical trials for Moderate to Severe Chronic Plaque-type Psoriasis

Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis

Start date: August 29, 2018
Phase: Phase 3
Study type: Interventional

This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis. 84 subjects (most with moderate severity) were enrolled. Subjects were stratified by weight and disease severity.

NCT ID: NCT03668470 Completed - Clinical trials for Adult Subjects With Type1Diabetes and Insulin Microsecretion

Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes

DIAMOND GLP1
Start date: January 31, 2019
Phase: Phase 2
Study type: Interventional

Some patients with type 1 diabetes (T1D) can still have some remaining insulin-positive cells in the pancreas and secrete little amounts of insulin. Despite the presence of residual beta cells, the HbA1C levels remain at high levels due to functional defects of insulin secretion associated with glucotoxicity. Previous trials have indicated that treatment with a Glucagon-like peptide 1 (GLP-1 )receptor agonist in T1D with some residual beta-cell function might improve glycemic control, reduce dose of insulin and risk of hypoglycemia. The general hypothesis of DIAMOND-GLP1 is that GLP1-R agonists will improve blood glucose After initial screening to select insulin microsecretors and a run-in period of one month, patients will be randomized into two arms and followed in parallel for 24 weeks : - Experimental group receiving 1.5 mg Dulaglutide s.c weekly in addition to their usual insulin regimen - Control group receiving placebo s.c weekly in addition to their usual insulin regimen. The primary endpoint is HbA1c value at 24 weeks

NCT ID: NCT03668210 Completed - Clinical trials for Anterior Cruciate Ligament Rupture

Risk Factor of Anterior Cruciate Ligament Rupture After Ligamentoplasty : What is the Importance of a Relative Deficit of Contralateral Hamstrings Assessed by Isokinetic in Postoperative ?

DIS-RRACT
Start date: July 31, 2017
Phase:
Study type: Observational

Anterior cruciate ligament (ACL) is a common pathology (37 000 operations in 2006, nearly 43 000 in 2012 in France) justifying more and more operating indications in younger and younger patients. 70-80% of ACL ruptures occur without contact, which makes it a major public health interest because of its frequency and accessibility in terms of prevention. The place of isokinetic assessment is important pre and postoperatively so that it has become systematic.